Scarica l'app Stockscreener
0.6993
2.84%
0.0193
Dopo l'orario di chiusura:
.68
-0.0193
-2.76%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$0.68
Aprire:
$0.69
Volume 24 ore:
177.89K
Relative Volume:
1.08
Capitalizzazione di mercato:
$12.03M
Reddito:
-
Utile/perdita netta:
$-52.53M
Rapporto P/E:
-0.1911
EPS:
-3.66
Flusso di cassa netto:
$-39.93M
1 W Prestazione:
-10.23%
1M Prestazione:
-30.76%
6M Prestazione:
-43.60%
1 anno Prestazione:
-55.17%
Intervallo 1D:
$0.6614
$0.6997
Intervallo di 1 settimana:
$0.66
$0.7957
Portata 52W:
$0.66
$3.10
Unity Biotechnology Inc Stock (UBX) Company Profile
Nome
Unity Biotechnology Inc
Settore
Industria
Telefono
(650) 416-1192
Indirizzo
285 EAST GRAND AVENUE, SOUTH SAN FRANCISCO, CA
Confronta UBX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
UBX
Unity Biotechnology Inc
|
0.6993 | 13.41M | 0 | -52.53M | -39.93M | -3.66 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Unity Biotechnology Inc Stock (UBX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-05-27 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2025-05-16 | Downgrade | Mizuho | Outperform → Neutral |
| 2024-08-22 | Iniziato | Rodman & Renshaw | Buy |
| 2023-11-16 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2022-01-04 | Aggiornamento | ROTH Capital | Neutral → Buy |
| 2021-11-10 | Aggiornamento | Mizuho | Neutral → Buy |
| 2021-06-28 | Aggiornamento | Citigroup | Sell → Buy |
| 2021-06-07 | Iniziato | H.C. Wainwright | Buy |
| 2021-02-16 | Downgrade | Citigroup | Neutral → Sell |
| 2020-08-18 | Downgrade | Citigroup | Buy → Neutral |
| 2020-08-18 | Downgrade | Mizuho | Buy → Neutral |
| 2020-08-18 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2020-08-17 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-28 | Iniziato | ROTH Capital | Buy |
| 2019-12-12 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-03-07 | Iniziato | Cantor Fitzgerald | Overweight |
| 2018-09-07 | Iniziato | Mizuho | Buy |
| 2018-05-29 | Iniziato | Citigroup | Buy |
| 2018-05-29 | Iniziato | Goldman | Neutral |
| 2018-05-29 | Iniziato | Morgan Stanley | Overweight |
Mostra tutto
Unity Biotechnology Inc Borsa (UBX) Ultime notizie
HC Wainwright Issues Optimistic Forecast for UBX Earnings - Defense World
Unity Biotechnology stock hits 52-week low at $0.66 - Investing.com
Unity Biotechnology stock hits 52-week low at $0.66 By Investing.com - Investing.com India
Fierce Biotech Layoff Tracker 2025: Keros cuts 70 jobs; iTeos winds down - Fierce Biotech
HC Wainwright & Co. Downgrades Unity Biotechnology (LSE:0YC0) - Nasdaq
Unity Biotechnology (NASDAQ:UBX) Receives Neutral Rating from HC Wainwright - Defense World
Unity Biotech stock rating downgraded at H.C. Wainwright By Investing.com - Investing.com Nigeria
This United States Steel Analyst Is No Longer Bullish; Here Are Top 3 Downgrades For Tuesday - Benzinga
Unity Biotechnology (UBX) Downgraded Amid Strategic Shifts | UBX Stock News - GuruFocus
HC Wainwright Downgrades Unity Biotechnology to Neutral From Buy, Adjusts Price Target to $2 From $4 - marketscreener.com
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Pr - GuruFocus
Unity Biotechnology (UBX) Downgrade: HC Wainwright & Co. Cuts Price Target | UBX Stock News - GuruFocus
Biotech company once valued at $700 million slashes entire workforce - MSN
Unity Biotechnology (NASDAQ:UBX) Rating Lowered to “Neutral” at Mizuho - Defense World
Mizuho cuts Unity Biotech stock rating, slashes price target to $1 - Investing.com Nigeria
Mizuho Downgrades Unity Biotechnology to Neutral From Outperform After Diabetic Edema Treatment Misses Primary Endpoint, Cuts Price Target to $1 From $6 - marketscreener.com
Unity Biotechnology (UBX) Downgraded Amid Trials and Strategic N - GuruFocus
Unity Biotechnology (UBX) to Release Earnings on Tuesday - Defense World
Bay Area biotech company Unity, once worth $700M, lays off entire remaining workforce - MSN
'It's a mess out there': More biotech layoffs mean stiff competition for jobs at emerging companies - The Business Journals
Renaissance Technologies LLC Sells 16,759 Shares of Unity Biotechnology, Inc. (NASDAQ:UBX) - Defense World
Bluebird pleads for deal support; Unity, Mersana lay off staff - BioPharma Dive
Bay Area biotech company lays off every single worker, including CEO - SFGATE
Finance Watch: Unity Lays Off All Employees As It Evaluates Alternatives - insights.citeline.com
UNITY Biotechnology (UBX) Reports Promising 36-Week Results from ASPIRE Trial | UBX Stock News - GuruFocus
Unity Biotechnology Explores Strategic Alternatives Post-ASPIRE Study - TipRanks
UNITY Biotechnology Estimates $3.7 Million Expenses For Reduction In Force - marketscreener.com
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of UBX1325 in Diabetic Macular Edema and Provides Corporate Updates - The Manila Times
UNITY Biotechnology Announces Complete 36-Week Results from - GlobeNewswire
UNITY Biotechnology Announces Complete 36-Week Results from the ASPIRE Phase 2b Study of - Bluefield Daily Telegraph
UNITY's New DME Treatment Rivals Aflibercept in Phase 2b Trial, Company Explores Strategic Options - Stock Titan
UNITY Biotechnology to Present 36-Week Data from ASPIRE Phase 2B Study at ARVO 2025 Annual Meeting - Nasdaq
UNITY Biotechnology to Present at the ARVO 2025 Annual Meeting - The Manila Times
UNITY Biotechnology tanks after failing to meet goal in eye disorder treatment trial - MSN
Chardan Capital Brokers Decrease Earnings Estimates for UBX - Defense World
Form 8-KCurrent report - ADVFN
HC Wainwright Issues Positive Outlook for UBX Earnings - Defense World
HC Wainwright Reiterates “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Chardan Capital Reaffirms “Buy” Rating for Unity Biotechnology (NASDAQ:UBX) - Defense World
Unity Biotechnology Reports Q1 2025 Financials and Study Updates - TipRanks
H.C. Wainwright maintains $4 target on Unity Biotech stock - Investing.com Australia
Unity Biotechnology (UBX) Reports $16.9M in Cash, Prepares for F - GuruFocus
H.C. Wainwright maintains $4 target on Unity Biotech stock By Investing.com - Investing.com Nigeria
UNITY Biotechnology (UBX) Shows Promise with Senolytic UBX1325 i - GuruFocus
UNITY Biotechnology Announces Publication in NEJM Evidence - GlobeNewswire
Revolutionary DME Drug Maintains Vision Improvement for 12 Months After Just One Dose, NEJM Study Shows - Stock Titan
UNITY Biotechnology, Inc. Reports First Quarter 2025 Financial R - GuruFocus
Unity Biotechnology Inc Azioni (UBX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.89%
3.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):